145 related articles for article (PubMed ID: 12740258)
1. A longitudinal study of alpha1-antitrypsin phenotypes and decline in FEV1 in a community population.
Silva GE; Sherrill DL; Guerra S; Barbee RA
Chest; 2003 May; 123(5):1435-40. PubMed ID: 12740258
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ alpha1-antitrypsin phenotype.
Silva GE; Guerra S; Keim S; Barbee RA; Sherrill DL
Chest; 2008 May; 133(5):1095-100. PubMed ID: 18263681
[TBL] [Abstract][Full Text] [Related]
3. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes.
Molloy K; Hersh CP; Morris VB; Carroll TP; O'Connor CA; Lasky-Su JA; Greene CM; O'Neill SJ; Silverman EK; McElvaney NG
Am J Respir Crit Care Med; 2014 Feb; 189(4):419-27. PubMed ID: 24428606
[TBL] [Abstract][Full Text] [Related]
4. Effects of smoking and intermediate alpha 1-antitrypsin deficiency (PiMZ) on lung function.
Eriksson S; Lindell SE; Wiberg R
Eur J Respir Dis; 1985 Oct; 67(4):279-85. PubMed ID: 3878302
[TBL] [Abstract][Full Text] [Related]
5. Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups.
Foreman MG; Wilson C; DeMeo DL; Hersh CP; Beaty TH; Cho MH; Ziniti J; Curran-Everett D; Criner G; Hokanson JE; Brantly M; Rouhani FN; Sandhaus RA; Crapo JD; Silverman EK;
Ann Am Thorac Soc; 2017 Aug; 14(8):1280-1287. PubMed ID: 28380308
[TBL] [Abstract][Full Text] [Related]
6. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
7. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
Sclar DA; Evans MA; Robison LM; Skaer TL
Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
[TBL] [Abstract][Full Text] [Related]
8. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
9. IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency.
Demeo DL; Campbell EJ; Barker AF; Brantly ML; Eden E; McElvaney NG; Rennard SI; Sandhaus RA; Stocks JM; Stoller JK; Strange C; Turino G; Silverman EK
Am J Respir Cell Mol Biol; 2008 Jan; 38(1):114-20. PubMed ID: 17690329
[TBL] [Abstract][Full Text] [Related]
10. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort.
Thun GA; Ferrarotti I; Imboden M; Rochat T; Gerbase M; Kronenberg F; Bridevaux PO; Zemp E; Zorzetto M; Ottaviani S; Russi EW; Luisetti M; Probst-Hensch NM
PLoS One; 2012; 7(8):e42728. PubMed ID: 22912729
[TBL] [Abstract][Full Text] [Related]
11. Interactions between SERPINA1 PiMZ genotype, occupational exposure and lung function decline.
Mehta AJ; Thun GA; Imboden M; Ferrarotti I; Keidel D; Künzli N; Kromhout H; Miedinger D; Phuleria H; Rochat T; Russi EW; Schindler C; Schwartz J; Vermeulen R; Luisetti M; Probst-Hensch N;
Occup Environ Med; 2014 Apr; 71(4):234-40. PubMed ID: 24213563
[TBL] [Abstract][Full Text] [Related]
12. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
Stockley RA; Edgar RG; Pillai A; Turner AM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
[TBL] [Abstract][Full Text] [Related]
13. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: evidence supporting targeted screening.
de Serres FJ; Blanco I; Fernández-Bustillo E
COPD; 2006 Aug; 3(3):133-9. PubMed ID: 17240615
[TBL] [Abstract][Full Text] [Related]
14. Alleles of the alpha-1-antitrypsin phenotype in patients with aortic aneurysms.
Schardey HM; Hernandez-Richter T; Klueppelberg U; Tutsch-Bauer E; Lauterjung L
J Cardiovasc Surg (Torino); 1998 Oct; 39(5):535-9. PubMed ID: 9833707
[TBL] [Abstract][Full Text] [Related]
15. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry.
Eden E; Hammel J; Rouhani FN; Brantly ML; Barker AF; Buist AS; Fallat RJ; Stoller JK; Crystal RG; Turino GM
Chest; 2003 Mar; 123(3):765-71. PubMed ID: 12628876
[TBL] [Abstract][Full Text] [Related]
16. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.
Dawkins PA; Dawkins CL; Wood AM; Nightingale PG; Stockley JA; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1338-44. PubMed ID: 19164359
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal lung function study in heterozygous PiMZ phenotype subjects.
Tarján E; Magyar P; Váczi Z; Lantos A; Vaszár L
Eur Respir J; 1994 Dec; 7(12):2199-204. PubMed ID: 7713204
[TBL] [Abstract][Full Text] [Related]
18. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals.
Bernspång E; Wollmer P; Sveger T; Piitulainen E
Respir Med; 2009 Jun; 103(6):861-5. PubMed ID: 19181511
[TBL] [Abstract][Full Text] [Related]
19. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.
Tonelli AR; Rouhani F; Li N; Schreck P; Brantly ML
Int J Chron Obstruct Pulmon Dis; 2009; 4():443-52. PubMed ID: 20054436
[TBL] [Abstract][Full Text] [Related]
20. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Respir Med; 2017 Sep; 130():1-8. PubMed ID: 29206626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
